Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Roche Holding AG ADR | CT388-103 | Obesity | Phase 2 | Data Released | Oral | Endocrinology |
| Roche Holding AG ADR | Lunsumio (mosunetuzumab) - (MorningSun) | Diffuse large B-cell lymphoma | Phase 2 | Ongoing | Intravenous | Oncology |
| Roche Holding AG ADR | Trastuzumab imbotolimod (BDC-1001) with Enhertu (pertuzumab) | HER2-positive breast, colorectal, endometrial, and gastroesophageal cancers | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Roche Holding AG ADR | Fenebrutinib - (FENopta) | Multiple sclerosis (MS) | Phase 2 | Oral | Neurology | |
| Roche Holding AG ADR | SRF388 + Atezolizumab + Bevacizumab | Hepatocellular carcinoma (HCC) | Phase 2 | Ongoing | Intravenous | Oncology |
| Roche Holding AG ADR | IONIS-FB-LRx - (GOLDEN) | Geographic atrophy due to age-related macular degeneration (AMD) | Phase 2 | Trial Discontinued | Subcutaneous | Opthalmic |
| Roche Holding AG ADR | EVRYSDI (risdiplam) - (JEWELFISH) | SMA type 1/2/3 switching | Phase 2 | Trial Completed | Oral | Genetic Disorder |
| Roche Holding AG ADR | LSTA1 (CEND-1) with Atezolizumab (Tecentriq) | Metastatic pancreatic ductal adenocarcinoma (mPDAC) | Phase 2 | Enrollment Initiation | Intravenous | Oncology |
